Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits
This newly indexed research record examines “Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits.” Use the linked GlobeNewswire publication to assess the study design, population, methods, findings and limitations; an indexed record alone should not be read as clinical guidance.
Open original source ↗Collected Nov 9, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.